Background
Main text
Ovarian organoids
Fallopian tube organoids
Mechanism of action | Function | Significance in reproductive organoid cultures | Ref | ||
---|---|---|---|---|---|
Frequently used factors | Noggin | Binds and inactivates members of the TGF-β superfamily signaling proteins, such as BMP4. | Allows for long-term expansion of organoids by preventing differentiation. | The lack of Noggin resulted in reduced numbers and/or smaller human EMO. The lack of Noggin growth markedly reduced the expansion and passageability of mouse EMO. Limited differentiation and promoted trophoblast survival in CTB-orgs. | |
RSPO1 | Interacts with WNT4 in the process of female sex development. Potentiates the cellular response to Wnts. | Facilitates the growth, expansion, and long-term culture of organoids. Plays a crucial role in formation and stem cell maintenance of FTO. | The lack of RSPO1 resulted in reduced numbers and/or smaller human EMO. Removal of RSPO1 alone did not affect mouse EMO formation efficiency. The lack of RSPO1 markedly reduced growth, expansion and passageability of mouse EMO. RSPO1 was required for efficient, long-term human EMO expansion. In the absence of RSPO1, human organoids could no longer be passaged after P3. Addition of RSPO1 increased the FTO size. RSPO1 is not absolutely required for long-term maintenance of mouse FTE organoids. Addition of RSPO1 increased differentiation of FTE organoids toward the ciliated lineage. Withdrawal of RSPO1 promoted trophoblast outgrowth from the outer CTB layers and expression of HLA-G at distal sites from the CTB-orgs. Critical for maintenance of CTB-orgs. | ||
WNT3A | The ligand of the canonical Wnt signaling pathway, Interacts with the LRP6/Frizzled receptor complex | Crucial for maintenance of stable growth over time. | The lack of WNT3A markedly reduced growth, expansion and passageability of mouse EMO. The presence of WNT3A (alone or together with RSPO1) enhanced the efficiency of mouse EMO formation. WNT3A was not needed for further expansion and passaging of human EMO. | [4] | |
HGF | Activates a tyrosine kinase signaling cascade after binding to the proto-oncogene c-Met receptor | Epithelial-cell mitogen. | The lack of HGF resulted in reduced numbers and/or smaller human EMO. Limit differentiation and promote trophoblast survival in CTB-orgs | ||
EGF | Activates the RAS/RAF/MEK/ERK signaling pathway | Epithelial-cell mitogen. Crucial for maintenance of stable growth over time. Supports proliferation and differentiation of FTE cells. | The lack of EGF resulted in reduced numbers and/or smaller human EMO. The lack of EGF resulted in markedly reduced growth, expansion, and passageability of mouse EMO. Required for long-term expansion of CTB-orgs. | ||
FGF10 | Acts mostly on the epithelium via Fgfr2b. | Epithelial-cell mitogens. | |||
Prostaglandin E2 | Binding and activation of the prostaglandin E2 receptor. | Critical for maintenance of CTB-orgs. | [5] | ||
Nicotinamide | A form of vitamin B3. | Withdrawal of nicotinamide had the strongest effect on the numbers of EMO that formed. | [3] | ||
Molecule inhibitors | Y27632 | Inhibits anoikis of dissociated cells. | Important for long-term culture and passaging of organoids. | ||
A-83-01 | Alk3/4/5 inhibitor. Blocks the TGF-β pathway. | Maintains epithelial-cell features | The lack of A-83-01 resulted in reduced numbers and/or smaller human EMO. Critical for maintenance of CTB-ORGs. Required for long-term expansion of CTB-orgs. | ||
SB202190 | p38 inhibitor. | Decreasing concentrations of p38i were beneficial for long-term expansion of endometrial cancer organoids. | [24] | ||
SB431542 | TGF-β R kinase inhibitor IV. | Crucial for quasi-indefinite expansion of FTO. | Without TGF-β, RK inhibitor FTO had slower expansion and finally growth arrest by four to six passages (three to four months). Important for formation and maintenance of large FTE organoids. | ||
CHIR99021 | Inhibitor of GSK3. | Critical for maintenance of CTB-orgs. | [5] |
Organoids | Source | Culture conditions | Cell types in organoids | Matrix | Generation efficiency | Reference |
---|---|---|---|---|---|---|
Ovarian cancer | Ovarian cancer tissue | Establishment: Advanced DMEM/F12, Glutamax, HEPES, Noggin, Rspo1, WNT3A, B27, FGF10, bFGF, nicotinamide, N-acetyl-L-cysteine, A83–01, Heregulinβ-1, hEGF, IGF-1, HGF, Forskolin, Hydrocortisone, NRG1, p38i (SB203580), β-Estradiol, Y-27632 Test components: carboplatin, paclitaxel, alpelisib, pictilisib, MK2206, AZD8055, Niraparib, adavosertib, gemcitabine, doxorubicin, nutlin-3 | Disease and original tumor phenotype | Cultrex growth factor reduced BME type 2 | 33–65% | |
Fallopian tube | human iPSC lines (87iCTR-n3, 01iMEC-n4, 14iCTR-n6) | Mesoderm induction: Activin A, CHIR99021, Y27632 Intermediate mesoderm induction: BMP4, CHIR99021, Y27632 The fallopian tube epithelial cells differentiation: WNT4, Follistatin Establishment: DMEM/F12, reconstituted Ultroser, Y-27632, estrogen, progesterone, conditioned media from FTE cells Maturation: cultured in 3D Matrigel for an extended period with estrogen and progesterone supplemented media | Ciliated (TUBB4A and FOXJ1) cells secretory (PAX8) cells | Matrigel | NR | [22] |
Lin − EPCAM+ FTE cells | Establishment: Advanced DMEM/F12, GlutaMAX, B27, EGF, TGFBR1 Kinase Inhibitor IV, Y-27632 Differentiation: RSPO1 | PAX8+ secretory cells acetylated tubulin (AcTUB) + ciliated cells | Matrigel | NR | [23] | |
Epithelial progenitor (EpCAM+) cell | Establishment: Advanced DMEM/F12, conditioned human Wnt3A medium, conditioned human RSPO1 medium, GlutaMAX, B27, N2, human EGF, human noggin, human FGF10, nicotinamide, Y-27632, TGF-β R Kinase Inhibitor IV hormonal stimulation: beta-oestradiol, progesterone | Pax8-positive secretory cells Pax8 negative, acetylated tubulin-positive ciliated cells | Matrigel | NR | [25] | |
Endometrium | the mouse endometrial glandular-type fragments | Establishment: DMEM/F12, GlutaMAX, B27, ITS, FGF10, nicotinamide, WNT3A; R-spondin 1, Noggin, A83–01 Hormonal stimulation: beta-oestradiol, progesterone | secretory cells ciliated cells | Matrigel | NR | [4] |
the human endometrial glandular-type fragments | Establishment: WNT3A; R-spondin 1, EGF, FGF10, Noggin, A83–01, ITS, N-acetyl-L-cysteine, p38 inhibitor SB202190Hormonal stimulation: beta-oestradiol, progesterone | secretory cells ciliated cells | Matrigel | NR | [4] | |
Dissociated endometrial cancer cells | Establishment: DMEM/F12, B27, Glutamax, N-acetyl cysteine, Primocin, nicotinamide, A 83–01, SB 202190, Y- 27632, 17-A estradiol Test components: Megestrol acetate, fulvestrant, letrozole, mifepristone, erlotinib, linsitinib; Selleckchem, BGJ-398, BBI608, cisplatin, paclitaxel. | Epithelial cells mesenchymal derivatives | growth factor reduced BME type 2 | NR | [26] | |
Endometrial epithelial cells | Establishment: ExM: Advanced DMEM/F12, N2, B27 minus vitamin A, Primocin, N-Acetyl-L-cysteine, L-glutamine, Recombinant human EGF, Recombinant human Noggin, Recombinant human Rspondin-1, Recombinant human FGF-10, Recombinant human HGF, ALK-4, −5, −7 inhibitor A83–01, Nicotinamide Differentiation: β-oestradiol, progesterone, cAMP, prolactin, human chorionic gonadotropin, human placental lactogen Hormonal stimulation: β-oestradiol, progesterone, cAMP | secretory (PAEP+) cells ciliated (acetylated-α-tubulin+) cells | Matrigel | 100% | [3] | |
Endometriotic epithelial cells (ECT-O) Epithelial cell from hyperplastic endometrium (HYP-O) | Establishment; SOM; DMEM/F12 + L-glutamine and Hepes, RSPO1-conditioned medium, Noggin, B27, N2, Glutamax, Insulin Transferrin Selenium, Nicotinamide, A83–01, N-acetyl L-cysteine, EGF, bFGF, FGF-10, SB202190 (p38i) | secretory cells ciliated cells | Matrigel | ECT-O; 60% HYP-O; 70% | [24] | |
Epithelial cell from endometrial cancer | Establishment; SOM; DMEM/F12 + L-glutamine and Hepes, RSPO1-conditioned medium, Noggin, B27, N2, Glutamax, Insulin Transferrin Selenium, Nicotinamide, A83–01, N-acetyl L-cysteine, EGF, bFGF, FGF-10, insulin-like growth factor 1 (IGF1), hepatocyte growth factor (HGF) and lipids Test components: paclitaxel, 5-fluorouracil, carboplatin, doxorubicin and everolimus | NR | Matrigel | EC-O; 40%; | [24] | |
Trophoblast | villous cytotrophoblasts (vCTBs), purified from pooled first-trimester placental tissues | Establishment: basic trophoblast organoid medium (b-TOM): advanced DMEM/F12, HEPES, B27, N2, glutamine, R-spondin, A83–01, rhEGF, rmHGF, prostaglandin E2, CHIR99021, Noggin, EGF, R-spondin, CHIR99021, A83–01 Differentiation: lacking R-spondin and CHIR99021, inhibitor of Wnt response-1 (IWR-1) | cytotrophoblasts (CTB) syncytiotrophoblasts (STB) extravillous trophoblast (EVT) | Matrigel | 100% | [5] |
trophoblast-enriched cell suspensions | Establishment: basal trophoblast organoid medium (TOM): EGF, FGF2, CHIR99021, A83–01, R-spondin 1, HGF, PGE2, Y-27632, nicotinamideDifferentiation: EVT differentiation medium (EVTM): advanced DMEM/ F12, 2-mercaptoethanol, BSA, ITS-X, NRG1, A83–01, KSR. Typically after days 7–10, the medium was changed to EVTM without NRG1 for a further 7–10 days. | syncytiotrophoblast (SCT) villous cytotrophoblast (VCT) HLA-G+ extravillous trophoblast cells (EVT) cells | Matrigel | 91% | [27] | |
Cervical organoid | cervical clear cell carcinoma cells | Establishment: DMEM/F12, human EGF, R-spondin1, Noggin, Y27632, Jagged-1, l-glutamine Test components: paclitaxel, cisplatin, gemcitabine hydrochloride, crizotinib, and SU11274 | Atypical cells with clear cytoplasm concordant with morphological features of the original tumor | Matrigel | [28] |